SAVA Projected Dividend Yield
Cassava Sciences Inc ( NASDAQ : SAVA )Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on neuroscience. Co.'s science is based on stabilizing, but not removing, a critical protein in the Alzheimer's brain. Its scientific approach for the treatment of Alzheimer's disease seeks to simultaneously suppress both neurodegeneration and neuroinflammation. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer's disease dementia. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimer's brain. 21 YEAR PERFORMANCE RESULTS |
SAVA Dividend History Detail SAVA Dividend News SAVA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |